期刊文献+

厄贝沙坦对原发性高血压患者血小板活化的影响

下载PDF
导出
摘要 目的探讨原发性高血压(EH)患者应用厄贝沙坦治疗前后血清P-选择素水平变化及厄贝沙坦对血管内皮的保护作用。方法40例轻、中度原发性高血压患者作为EH组,进行8周的药物治疗,30例健康者为对照组。检测EH组服用厄贝沙坦治疗前后血压情况和血清P-选择素浓度水平。结果与健康对照组相比,EH患者血清P-选择素的浓度明显增高(P<0.05)。治疗8周后,EH患者血清P-选择素浓度均较前下降(P<0.05),且血压水平较治疗前明显降低(P<0.01)。EH组患者治疗前收缩压、舒张压水平与血清P-选择素浓度之间均无线性相关。结论轻、中度EH患者血清P-选择素浓度水平显著增高,提示存在动脉粥样硬化的发生、发展。厄贝沙坦在有效降压的同时,亦能降低EH患者血清P-选择素水平,可改善血管内皮功能。
出处 《中国医药指南》 2010年第9期82-83,共2页 Guide of China Medicine
  • 相关文献

参考文献6

  • 1Minuz P, Patrignani P, Gaino S,et al.Determinants of Platelet activation in human essential hypertension[J]. Hypertension,2004,43(1):64.
  • 2Ridker PM,Buring JE,Rifai N.Soluble P-selectin and the risk of future cardiovascular events[J].Circulation,2001,103(4):491-495.
  • 3Bemdt,Michael C.Induction of platelet-endothelial interactions in postcapillary venules in hypercholesterolemia: Critical role of P-selectin, arteriosclerosis,thrombosis & vascular[J].Biology,2003, 23(4):525-527.
  • 4Rosen BD,Saad MF, Shea S,et al. Hypertension and smoking are associated with reduced regional left ventricular function in asymptomatic individuals: the multiethnic study of atheroscterosis[J].J Am Coil Cardiol,2006,47(6): 1150-1158.
  • 5Arikan E,Sen S. Endothelial damage and hemostatic markers in patients with uncomplicated mild-to-moderate hypertension and relationship with risk factors[J]. Clin Appl Throm Hemost,2005,11 (2): 147-159.
  • 6鹿育萨,雷新宇,邸捷,黄淑田,李建民.卡托普利、缬沙坦对兔动脉粥样硬化斑块的干预作用[J].中华内科杂志,2005,44(6):425-427. 被引量:9

二级参考文献5

  • 1Weiss D, Sorescu D, Taylor WR. Angiotensin Ⅱ and atherosclerosis. Am J Cardiol,2001,87(8A):25C-32C.
  • 2Diet F, Pratt RE, Berry GJ, et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation, 1996,94:2756-2767.
  • 3Neri Serneri GG, Boddi M, Poggesi L, et al. Activation of cardiac renin-angiotensin system in unstable angina. J Am Coll Cardiol,2001,38:49-55.
  • 4Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 2000,342:145-153.
  • 5Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS. PROGRESS Management Committee. Perindopril Protection Against Recurrent Stroke Study. J Hypertens Suppl, 1996,14:S41-S45.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部